網誌文章搜尋建議

給多發性硬化症MS病友和親友的建議:
如要搜尋站內相關文章可多利用
"搜尋此網誌的文章內容"的功能,這樣就可以快速的找到你想要得資訊而不需要從第一篇開始看了.
有關CCSVI(靜脈血管窄化及手術的資訊)可在相關連結以及相關MS blog內

推薦頻道:Gimmy a break

2015年1月17日 星期六

印度的幹細胞治療成果(成功案例):幹細胞+Liberation治療(CCSVI)

幹細胞,就不用我多說,是解決神經系統受損的終極法寶,今日於最新的加拿大消息報導了一位加拿大女士至印度進行了實驗性幹細胞手術後行動力因此恢復,附上原報導內容如下:

一位從加拿大薩斯喀徹溫省的MS病患遠赴印度做了實驗性的幹細胞療法,主要是由加拿大溫尼伯的一家公司[Regenetek Research]的CEO徵求MS病患去印度施行這樣的手術(印度已經核可)。這手術包含靜脈擴張和幹細胞治療。該CEO也是這個研究的領導人,但是有些病患質疑該CEO的身分而且病人術後的聯繫關懷沒有做好。

A multiple sclerosis patient from Saskatchewan who travelled to India to undergo an experimental stem cell treatment is defending the Winnipeg company that recruited her for the therapy and study, which some have called into question.
Regenetek Research has been under scrutiny following media reports this week about its CEO, Doug Broeska.
Broeska had recruited MS patients to take part in the experimental and expensive study, which was administered in India, involving stem cell injections combined with so-called liberation therapy, which involves the widening of veins in the neck.
He was, until recently, also the principal researcher for the study related to the treatment.
However, some patients have questioned Broeska's qualifications as a researcher. As well, some say the therapy did not work for them, and they were not receive proper followup.
Other patients, like Linda Friesen of Tisdale, Sask., reported having success with the therapy.
"I am shocked right now. I am surprised in what has been said," she told CBC News when asked about the latest allegations.
Friesen said she used to rely on a wheelchair because of her MS and injuries from a car accident, but she left that wheelchair behind at the hospital in India after undergoing the experimental treatment — which cost her $34,000 US — in 2013.
"It's so amazing to have this opportunity to be part of the research," she said in a promotional video produced by Regenetek.

Friesen told CBC News that the company has paid her to help other MS patients in Saskatchewan with their paperwork.
另一位病患 Linda Friesen 則被報導是一個成功的案例。
"聽到那個質疑讓我很震驚",她過去需要倚賴輪椅(因為MS和一場車禍),但是在2013年去了印度花了3萬4千美元做這個手術之後,就不需要輪椅了。能參與這個研究很棒。

Regenetek responds

In a statement issued Thursday, Regenetek Research says its stands behind its role in the stem cell therapy study, "namely as researchers tracking participant progress following medical treatment, with such medical treatment having been provided by third-party medical practitioners located in India.
"Regenetek Research and its researchers do not provide medical treatment in connection with the clinical study," the company's statement reads in part.
"Further, the study was never intended to replace other medical treatment and individuals were directed to stay in contact with their treating physicians. We are scientists simply tracking the progress of participants who have chosen to attempt innovative therapy options and to have their results noted by us for scientific study."

Regenetek公司的聲明全文的一部分如下:Regenetek及其研究人員不提供治療臨床研究
  此外,這項研究是從來沒有打算取代其他的治療方式,而每個病患需要和他們的手術醫師保持聯繫。我們科學家只是簡單地追蹤選擇這些創新治療方式手術後的進展,並做一註記
Regenetek Research's Facebook page
Winnipeg-based Regenetek Research issued a statement Thursday in response to media reports about Doug Broeska, who had recruited MS patients to take part in the experimental and expensive study involving stem cell injections combined with so-called liberation therapy. (CBC)
Last month, the ethics committee with the hospital in India where the treatment was being performed ordered Broeska to step down as principal investigator, saying his lack of credentials and medical followup "violated international ethical standards."
Broeska had stated on a LinkedIn profile that he has a PhD from the University of Manitoba, but the university confirmed that neither a Doug Broeska nor a Henry Douglas Broeska graduated from there. The profile has since been removed from the site.
The International Cellular Medicine Society and the College of Physicians and Surgeons of Manitoba both said they have no record of Broeska as a member.
Broeska has not responded to requests from CBC News for an interview. The company's statement was not signed by him, and it does not directly address specific questions about his credentials.
Broeska has defended his qualifications to another media outlet and in emails to patients.
In one message, obtained by CBC News, he told a patient that his credentials are sound and he is "competent to perform research of this type."

Experts concerned about fallout

Meanwhile, some in the scientific community say they're worried that the fallout from this and other controversies could result in confusion about stem cell research as a whole.
Dr. Duncan Stewart of the Ottawa Hospital Research Institute, which is conducting research on using genetically enhanced stem cells to repair damaged heart muscle, said the field is in its early days and has tremendous promise.
"It only takes one high-profile significant problem to make everyone very nervous," he said.
Tim Caulfield, the Canada Research Chair in Health Law and Policy at the University of Alberta, agrees.
"That's a really good example of how the availability of these treatments, marketing of these treatments, can lead people to believe stem cell therapy is much further along than it really is," he said.
The Canadian Stem Cell Foundation says it wants the federal government to invest $50 million in stem-cell research in each of the next 10 years.
It also wants Ottawa to streamline the process for clinical trials in this country "so that Canadians that are suffering have access to treatments that are safe and proven to be effective," said James Price, the foundation's president and CEO.

原文出處

 附上 Regenetek Research Inc 所提供的 影片共三個病人的成功案例
 
 Study Subject: Linda Friesen

Study Subject: Deb O'Connell

Study Subject: Martine Millard 

不過也有不好的例子

Lee Chuckry, 47, of Airdrie, Alta., said he spent $34,000 for the therapy only to find out his MS has worsened.
"I think it's just a big fraudulent scam," he told CBC News on Wednesday.
Chuckry, who has been battling MS for over a decade, said the treatment involved the widening of the veins in his neck — a practice advocates call liberation therapy — plus the injection of stem cells into his veins and spinal column.

Lee Chuckry
Lee Chuckry of Airdrie, Alta., says he was recruited to undergo experimental stem cell therapy in India. After travelling there and spending $34,000 on the treatment, Chuckry says he believes his MS has worsened. (CBC)

 更多相關報導閱讀:

http://www.cbc.ca/news/canada/manitoba/ms-patients-question-credentials-of-winnipeg-man-involved-in-stem-cell-therapy-1.2901057

 小提醒:此為幹細胞於youtube上最新發現的影片(來自於病友的說法)為結合靜脈擴張+幹細胞注射的一種新型療法,還需要多加判別和注意。將會持續的追蹤.....

 


Share/Bookmark

2014 MS研究年終回顧 以及 硬化在腦部和脊髓兩處的差異


不同于其它类型 MS 研究上的飞速进展,由于缺少检测疾病进展时间、形式与原因的可靠方式,进展型 MS 目前仍然缺乏认可的治疗方式。
而 2014 年 MS 表型工作组,对进展型 MS 重新进行准确定义,相关专家回顾了 1996 年进展型 MS 的分类方法(原发性进展、继发性进展、进展复发型),将临床及 MRI 数据进行更新整合。
2014 柳叶刀年终回顾之多发性硬化症篇 
上圖顯示病灶在大腦和脊髓的主要不同之處 
(由我過去所接觸過的病友來看,脊髓受傷的恢復率比大腦來的小和低,如果脊髓受到傷害,某種程度上會和脊髓損傷的症狀非常雷同。但是如果傷害在腦幹,則有立即的生命危險)

继而提出 2 点重要变动:1)需要通过每年临床及 MRI 结果,评估疾病活动性(复发、钆增强 MRI 病变、病灶明确增大);2)需要每年评估疾病进展性(通过明确的时间间隔,确认神经系统障碍的进展)。
最新分型准则,剔除了进展复发过程,并将原发进展及继发进展过程,统一命名为进展型 MS,随后再根据疾病活动性的存在与否(活动性、非活动性),以及疾病是否进展而分类。
定期跟踪炎症及神经退行性病变进展相关的症状与体征,或许有助于选择进展型 MS 患者亚群,从而筛选出能够受益于某些特异治疗手段的患者。MS 表型工作组强调,未来在 MS 表型定义的评估、确认、修改过程中,需要鉴定更好的生物标志物与非传统的影像学参数。
在上述背景下,Villar 博士及其同事评估了 IgM 单克隆区带,作为一种靶向于原发进展型 MS 炎症过程生物标志物的可行性。研究者通过横断面及纵向试验,评估了来自大型原发进展型 MS 患者队列的配对血清、CSF(脑脊液)样本。
研究显示,脑脊液 IgM 单克隆区带的存在,能够鉴定出临床过程更具侵犯性的原发进展型 MS。并且相比于没有 IgM 单克隆区带的患者而言,脑脊液 IgM 单克隆区带的存在提示患者 B 细胞比例更高、B 细胞绝对数计数更高,钆增强 MRI 病变数目更多。这些成果提示,或许与复发缓解型 MS 一样,进展型 MS 患者亚群也对抗炎症治疗反应良好。
Tur 博士及其同事展开了一项为期 5 年研究,纵向评估了 41 名早期原发进展型 MS 患者。研究发现,HLA-DRB1*15 等位基因,影响脑灰质、白质病变进展比率。相比于 HLA-DRB1*15 非携带者而言,携带该等位基因的患者大脑磁化传递率下降更快,并且 T2 病灶增加。
2014 柳叶刀年终回顾之多发性硬化症篇
然而,随着时间进展,HLA-DRB1*15 阳性与阴性组间,大脑白质、灰质、脊髓体积损失比率没有区别。研究支持以下可能性,即不同于 HLA-DRB1*15 阴性患者,HLA-DRB1*15 阳性的原发进展型 MS 患者,微观组织炎症损伤率更高,并且可能受益于早期、定向的干预疗法。
Du 博士及其同事强调,XY 性别染色体,在 CNS 神经退行性病变中具有突出作用。使用自身免疫性脑炎小鼠模型的研究显示,CNS 内为 XY 染色体的小鼠,临床疾病更加严重,并且脊髓、小脑、脑皮质神经退行性程度更高。
另外,X 性染色体上的 TLR7 基因,能够诱导神经元损伤,而相比于 XX 小鼠,TLR7 基因在 XY 小鼠皮质神经元内表达增加。这些结果或许可以部分解释,为何相比于女性,男性患者更倾向于罹患进展型 MS,而且疾病进展过程更快。

2014 年, MS 相关性疾病:NMO(视神经脊髓炎)和 NMO 谱系病的研究,也取得重大进展。致病血清抗体(AQP4 抗体),彻底改变了 NMO 及 NMO 谱系病的诊断与治疗方式。最近研究显示,针对髓鞘少突胶质细胞糖蛋白 (MOG) 的自身抗体,存在于一定比例的抗 AQP4 阴性 NMO 及 NMO 谱系病患者中。
抗 AQP4 阳性及抗 MOG 阳性的 NMO 谱系病患者,具有不同的临床及 MRI 特征。抗 MOG 抗体阳性患者(21.1% 抗 AQP4 阴性患者),多为男性(女 / 男为 0.6),一般侵犯视神经,但两侧往往同时恢复,且效果较好。
抗 MOG 阳性的 NMO 谱系病患者,未来需要展开进一步研究,首先要从其它可能表达抗 MOG 抗体的脱髓鞘疾病(急性脱髓鞘性脑炎或 MS)中鉴别出 NMO 谱系病,其次需要考虑抗 AQP4 与抗 MOG 抗体同时出现的情况。准确鉴定 AQP4 抗体阴性的 NMO 患者,可能有助于选择合适的治疗策略。
综上所述,这些成果提示,目前研究焦点正渐转移到 MS 及相关疾病表型标志物的检测上,并最终致力于实现个体化治疗目标。

Share/Bookmark